S_mary Human colorectal cancer tissue and matched uninvolved mucosa from 21 patients were examined by radioligand displacement for the presence of binding sites for bombesin-like peptides. Five cancers, but no univolved mucosa, expressed high-affinity, low-capacity bombesin binding sites (KYd = 6.53 nM, B.. = 58.6 fmol mg-' protein) of the gastrin-releasing peptide (GRP)-preferring subtype (IC50 4.8 nM).
Colorectal adenocarcinoma is the fourth most common cancer in the world (Parkin et a!., 1988) . It predominantly affects Westernised countries, where it is the second most common cause of cancer death, accounting for 19 000 deaths each year in the UK, 61 000 in the USA and 85 000 in the EU (Cancer Research Campaign Factsheets, 1993) . Understanding of the genetic basis of colorectal carcinoma is rapidly increasing with the discovery of the MCC (Kinzler et al., 1991a) , DCC (Fearon et al., 1990) , FAP (Kinzler et al., 1991b) and hMSH2 (Leach et al., 1993) loci. The growth of tumours, once established genetically, may also be influenced by local growth factors. This has been exploited in the treatment of breast cancer with oestrogen antagonists (Santen et al., 1990 ) and prostatic cancer with anti-androgens and luteinising hormone-releasing hormone (LHRH) antagonists (Gittes, 1991) . The gastrointestinal tract is a very rich source of peptide hormones, and it may be possible to affect the rate of growth of established tumours by antagonising endogenous trophic hormones.
Bombesin, an amphibian tetradecapeptide, is known to exert a wide range of effects on the mammalian gastrointestinal tract, and bombesin-like immunoreactivity has been demonstrated in the submucosal and myentenc plexuses throughout the gut. These data led to the search for mammalian bombesin-like peptides and the resultant discovery of gastrin-releasing peptide (GRP) (McDonald et al., 1979) and neuromedin B (NMB) (Minamino et al., 1983) . In the mammalian gut bombesin-like peptides regulate gut motility, influence the secretion of a large number of enteric peptide hormones and stimulate pancreatic exocrine secretion (reviewed in Sunday et al., 1988) . To date three bombesin-like peptide receptors have been described and cloned: the GRPpreferring subtype (GRP receptor) (Spindel et al., 1990) , found in the gut from oesophagus to rectum (reviewed in Sunday et al., 1988) ; the NMB-preferring subtype (NMB receptor) (Wada et al., 1991) , present in the oesophageal muscularis mucosa (von Schrenck et al., 1989) ; and bombesin receptor subtype 3 (BRS-3), present in the testis, uterus and lung cancer cells, but not in the rat gastrointestinal tract (Fathi et al., 1993) . Bombesin-like peptides are recognised mitogens potently stimulating the growth of Swiss 3T3 fibroblasts (Rozengurt et al., 1983) and human small-cell lung cancer cell lines (Weber et al., 1985) and thus may be mitogenic to receptor-bearing cells within the gut.
The aim of this present study was to examine colorectal cancer tissue and uninvolved mucosa for bombesin family receptors, and to characterise further any binding sites found.
Material and methods
All materials and methods used in this study have been previously described (Preston et al., 1993) . In brief, tumour tissue and adjacent uninvolved mucosa was collected at operation, snap frozen and stored at -70C until assayed. Binding studies were performed on membrane preparations prepared from tumour and mucosa. Membrane protein was incubated, six tubes for each point, with approximately 200pM ['5IJTyr"-BBS (Du Pont, Stevenage, UK) and unlabelled BBS (Bachem, Saffron Walden, UK) over the concentration range 1 x 10-" to 1 x 106 M. Scatchard analysis was performed on the binding data. In tumours which exhibited BBS binding, the binding studies were repeated, but on this occasion the binding site was further characterised using GRP and NMB (both Bachem) as competitors.
Results
Pathological details (Table I log10o [bombesinl (M) Figre At present we may only speculate as to the significance of GRP binding site expression on human colorectal cancer cells, but the expression of these receptors on cancerous cells but not on normal epithelium is becoming a widely described phenomenon (Giacchetti et al., 1990; Radulovic et al., 1991; Preston et al., 1993) and certainly warrants further study.
